Internationale Partnersuche

Innovation & Technologie Angebot

A French Technology Transfer Office offers a new adujvant which improves therapeutic vaccination.

Country of Origin: France
Reference Number: TOFR20180315001
Publication Date: 16 March 2018

Summary

A French Technology Transfer Office (TTO) offers a new adjuvant which improves therapeutic vaccination and more precisely the vaccines' immune response thanks to a patented micro-particle containing a new liposome.
The French TTO is looking for interested pharmacology corporates or biotechnology SMEs, either for a licensing agreement or a technical cooperation agreement.

Description

A French TTO acting on behalf major life science research labs in Paris Region, has designed and synthetized a new patented micro-particle which strongly improves the efficacy of a type of vaccines: ribonucleic acid (RNA) vaccines.

The proof of concept has been performed on Human Papilloma Virus (HPV) inoculated to mice, but this technology can be used for any kind of RNA vaccines (for infectious diseases and oncology) to treat both liquid and solid tumours such as breast or prostate cancers, HIV, tuberculosis…



Vaccination (or active immunotherapy) consists in inserting a specific antigen linked to the pathogenic against whom the body has to be protected by stimulating the immune system.



The innovation is based on the key role of liposomal vaccination. This innovative liposome is a particle formed by lipids and mannose motif which enclosed the antigen. This liposome targets immune cells (with adjuvant effect) which allows in situ antigen production, that is the reason of its protective effect.



The partner sought could be a company interested in :

- a license agreement as the TTO is ready to negotiate directly the patents rights for specific applications, or

- a technical cooperation agreement 



The French TTO is able to provide technical and legal assistance to facilitate the eventual partnership

Advantages and Innovations

The vaccination with this technology allows a better targeting of the immune cells.

Indeed, currently the vaccines on the market are not completely efficient because the antigen is not always in contact with the immune cells due to to a specificity default.	

The advantages of this new technology are:

-	specifically targeting cells, dendritic cells in particular (by a optimization of activation of these cells)

-	ability to facilitate antigen presentation

-	protection of synthetic mRNA from its degradation

-	avoiding the use of foreign DNA in cells (because RNA is used)

The vaccination with this technology improves the mouses survival of 30% compared to a classical vaccine approach

Stage Of Development

Prototype available for demonstration

Stage Of Development Comment

The proof of concept (POC) has been launched on Human Papilloma Virus (HPV)  in vivo (on the small animal).

Requested partner

The partner sought could be a company involved in the vaccination domain -not only on RNA vaccine- interested in developing some more efficient therapeutic vaccines.



A licensing agreement is open to manufacturing drugs firms which are able to drive pre-clinical testing of the new molecule, prior to its manufacturing and commercialization of the specific medicine for Papilloma Virus Human (PVH).

A technical cooperation agreement may also interest companies in biotechnology which are interested to develop new RNA vaccines.